Delving into the Latest Updates on ChAdV63.HIVconsv(University of Oxford) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication

Chronic Disease

Originator Organization

University of Oxford

Active Organization

University of Oxford

Inactive Organization

Imperial College London

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study will be a two-arm prospective 1:1 randomised controlled trial comparing:
Arm A: cART preferably including raltegravir (combination ART cART - control) Arm B: cART preferably including raltegravir (cART) plus ChAdV63.HIVconsv (ChAd) prime and MVA.HIVconsv (MVA) boost vaccines; followed by a 28-day course of vorinostat (10 doses in total).
We hypothesise that this intervention in primary HIV infection will confer a significant reduction in the latent HIV reservoir when compared with cART alone.
.

Start Date27 Nov 2015

Sponsor / Collaborator

Imperial College London

[+8]

NCT01151319

/ CompletedPhase 1IIT

A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults

This is a randomised, placebo-controlled, single-blind study designed to evaluate the safety and immunogenicity of three novel HIV vaccines.

Start Date01 Oct 2010

Sponsor / Collaborator

University of Oxford

100 Clinical Results associated with ChAdV63.HIVconsv(University of Oxford)

Login to view more data

100 Translational Medicine associated with ChAdV63.HIVconsv(University of Oxford)

Login to view more data

100 Patents (Medical) associated with ChAdV63.HIVconsv(University of Oxford)

Login to view more data

100 Deals associated with ChAdV63.HIVconsv(University of Oxford)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Phase 2	GB	University of Oxford	27 Nov 2015
Chronic Disease	Discovery	GB	Imperial College London	27 Nov 2015

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02336074 (RIVER, CTgov)	Phase 2	HIV Infections	60	Combination Antiretroviral Therapy (cART)+raltegravir (Control)	aylwurkvoc(qfmnkkvhwd) = fxlkofkgmx uowyllcjgz (erittkweih, tuswvitias - lphotaupxo) View more	-	25 Sep 2019
				Combination Antiretroviral Therapy (cART)+Vorinostat+MVA.HIVconsv (MVA)+ChAdV63.HIVconsv (ChAd)+raltegravir (Intervention)	aylwurkvoc(qfmnkkvhwd) = flohsjprvf uowyllcjgz (erittkweih, vcpgydnshk - nzxsdmwbyi) View more